As of 3:59pm ET
| +0.10 / +0.39%|
Aceto Corp. is engaged in the marketing, sales and distribution of pharmaceutical active ingredients and intermediates, finished dosage form generic pharmaceuticals, nutraceutical products, agricultural protection products and specialty chemicals. The company operates through there segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment includes finished dosage form generic drugs and nutraceutical products. It supplies the raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds and biochemicals used in pharmaceutical and nutritional preparations. The Pharmaceutical Ingredients segment consists of two product groups: Active Pharmaceutical Ingredients and Pharmaceutical Intermediates. The Performance Chemicals segment consists of two product groups: Specialty Chemicals and Agriculture Protection products. The Specialty chemicals includes a variety of chemicals which make plastics, surface coatings, textiles, fuels and lubricants perform to their designed capabilities. Its dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. This segment's organic intermediates are used in the production of agrochemicals. It also supplies diazos and couplers to the paper, film and electronics industries. The Agriculture protection products includes herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. This segment also includes a sprout inhibitor for potatoes and an herbicide for sugar cane. Aceto was founded in 1947 and is headquartered in Port Washington, NY.
|Salvatore J. Guccione||President, Chief Executive Officer & Director|
|Walter J. Kaczmarek||Chief Operating Officer|
|Douglas A. Roth||Chief Financial Officer, Treasurer & Senior VP|
|Steven S. Rogers||Secretary, Senior Vice President & General Counsel|
|Frank DeBenedittis||Senior VP-Corporate Business Development|